Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty

Journal of the American College of Cardiology

Volumn 34, Issue 5, 1999, Pages 1512-1521

  Buffon, Antonino ^a   Liuzzo, Giovanna ^a   Biasucci, Luigi M ^a   Pasqualetti, Patrizio ^b   Ramazzotti, Vito ^b   Rebuzzi, Antonio G ^a   Crea, Filippo ^a   Maseri, Attilio ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; SERUM AMYLOID A;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CORONARY ARTERY DILATATION; DIAGNOSTIC VALUE; FEMALE; GENDER; HUMAN; HYPERTENSION; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTENOSIS; SURGICAL RISK; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0033231339     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00348-4     Document Type: Article

References (35)

1. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84:1426-36.
2. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-35.
3. de Feyer PJ, Ruygrok PN. Coronary intervention: risk stratification and management of abrupt coronary occlusion. Eur Heart J 1995;16 Suppl L:L97-103.
4. The Epilog Investigators. Platelet glycoprotem IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
5. Macaya C, Serruys PW, Ruygrok P, et al. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. J Am Coll Cardiol 1996;27:255-61.
6. Detre KM, Holmes DR, Jr, Holubkov R, et al. Incidence and consequences of penprocedural occlusion of the 1985-1986 National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-50.
7. Thompson RC, Holmes DR, Jr, Gersh BJ, Bailey K. Predicting early and intermediate-term outcome of coronary angioplasty in the elderly. Circulation 1993;88:1579-87.
8. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Circulation 1990;82:1193-202.
9. Tan K, Sulke N, Taub N, Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. J Am Coll Cardiol 1995;25:855-65.
10. White CJ, Ramee SR, Collins TJ, et al. Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. Circulation 1996;93:253-8.
11. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064-71.
12. Tschoepe D, Schultheib HB, Kolarov P, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993;88:37-42.
13. Rensing BJ, Heramns WRM, Vos J, et al. Luminal narrowing after percutaneous coronary angioplasty: a study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Circulation 1993;88:975-85.
14. Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation 1994;90:1239-51.
15. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997;133:387-92.
16. Pietersma A, Kofflard M, de Wit EA, et al. Late luminal loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 1995;91:1320-5.
17. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995;92:31-8.
18. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403-9.
19. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
20. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 1995;748:501-7.
21. Ikeda U, Ikeda M, Oohara T, et al. Interleukin-6 stimulates the growth of vascular cells in a PDGF-dependent manner. Am J Physiol 1991;260:H1713-7.
22. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990;7:147-59.
23. Liuzzo G, Biasucci LM, Gallimore JR, et al. Prognostic value of C-reactive protein and plasma amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
24. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
25. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
26. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibbhn G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
27. Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassays for human CRP. Clin Chim Acta 1981;117:13-23.
28. Wilkins J, Gallimore JR, Tennent GA, et al. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem 1994;40:1284-90.
29. Clauss A. Gerinnungsphysiologishe Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-46.
30. Ambrose JA, Winters SL, Arora RR, et al. Coronary angiographic morphology in myocardial infarction: a link between pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol 1985;6:1233-8.
31. The TIMI Stud Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med 1985;312:932-6.
32. Leehmann KG, Melkert R, Serruys PW. Contributions of frequency distribution analysis to the understanding of coronary restenosis: a reappraisal of the Gaussian curve. Circulation 1996;93:1123-32.
33. Schömig A, Kastrati A, Elezi S, et al. Bimodal distribution of angiographic measures of restenosis six months after stent placement. Circulation 1997;96:3880-7.
34. Weintraub WS, Brown CL, Liberman HA, et al. Effect of restenosis at one previously dilated coronary site on the probability of restenosis at another previously dilated coronary site. Am J Cardiol 1993;72:1107-13.
35. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998;82:515-8.